EU industry needs all hands on deck to scale back MDR scrutiny clause
This article was originally published in Clinica
Executive Summary
Recent days have seen a welter of industry association concern following the European Parliament’s ENVI committee’s vote on the
You may also be interested in...
The Rozy View: US Medtechs Face New Reg Burdens On Entering EU Market
The EU MDR and IVDR have finally been adopted, which is good news in the sense that regulatory certainty is guaranteed, but bad news in terms of the extra compliance costs that industry, including US medtechs, will have to face in the coming years.
The Rozy View: Medtechs, Negotiate With India’s Regulators And Don't Give Up On Japan
Late to the regulatory game India's government authorities may be, but device companies need to be on their toes to not lose out on vast future market opportunities as the "Make in India" program takes shape. That is the view of international device regulatory and market access expert Ed Rozynski. And while India is on the up, is Japan losing its attractiveness?
Brazil's Anvisa thinks both big and small on medtech GMP regulatory changes
Brazil's medicines and medical devices regulatory authority, Anvisa, is not overlooking the needs of smaller device manufacturers as it moves to simplify and align its regulatory processes with those of established major countries.